← Travere Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $133.6m |
$154.9m
+15.98%
|
$164.2m
+6.01%
|
$175.3m
+6.75%
|
$198.3m
+13.11%
|
$227.5m
+14.71%
|
$212.0m
-6.80%
|
$145.2m
-31.50%
|
$233.2m
+60.55%
|
$490.7m
+110.45%
|
$591.3m
+20.50%
|
|
| Cost of Revenue | $4.6m |
$3.6m
-20.84%
|
$5.5m
+53.31%
|
$5.2m
-5.30%
|
$6.1m
+17.04%
|
$6.8m
+10.74%
|
$7.6m
+11.91%
|
$11.4m
+50.82%
|
$7.7m
-32.37%
|
$10.3m
+33.51%
|
$14.1m
+36.16%
|
|
| Gross Profit (Calculated) | $129.0m |
$151.3m
+17.28%
|
$158.7m
+4.88%
|
$170.1m
+7.17%
|
$192.2m
+12.99%
|
$220.7m
+14.83%
|
$204.4m
-7.38%
|
$133.8m
-34.55%
|
$225.4m
+68.50%
|
$480.4m
+113.10%
|
— | |
| Interest Income (Expense), Net | — | — | $5.5m | — | — | — | — | — | — | — | $11.6m | |
| Research and Development Expense | $70.9m | $78.2m | $123.8m | $141.0m | — | — | $7.5m | — | — | — | $227.1m | |
| Selling, General and Administrative Expense | $92.8m | $101.3m | $103.7m | $129.0m | $135.8m | $149.9m | $220.2m | $265.5m | $264.1m | $337.2m | $390.6m | |
| Amortization of Intangible Assets | $16.0m | $17.3m | $18.0m | $19.7m | $22.4m | $24.9m | $31.0m | $36.3m | $41.7m | $59.2m | — | |
| Operating Lease, Expense | — | — | — | $2.7m | $2.0m | $4.9m | $5.0m | $4.9m | $4.8m | $4.4m | — | |
| Restructuring Costs | — | — | — | — | — | — | — | $11.4m | — | — | — | |
| Operating Expenses | $191.8m | $208.7m | $244.3m | — | — | — | — | — | — | — | $631.8m | |
| Operating Income (Loss) | ($58.2m) |
($53.8m)
+7.60%
|
($80.0m)
-48.80%
|
($137.4m)
-71.62%
|
($176.2m)
-28.25%
|
($161.8m)
+8.17%
|
($266.6m)
-64.79%
|
($388.1m)
-45.61%
|
($323.8m)
+16.57%
|
($62.8m)
+80.60%
|
($40.5m)
+35.60%
|
|
| Debt Securities, Realized Gain (Loss) | $99k | ($186k) | $0 | $2.2m | ($176k) | ($1.2m) | ($2.5m) | $3.7m | ($374k) | ($383k) | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | $0 | $1.1m | ($464k) | ($112k) | $934k | — | $507k | — | ($700k) | ($300k) | — | |
| Foreign Currency Transaction Gain (Loss), Realized | $93k | ($339k) | $39k | $92k | ($1.5m) | $1.5m | $507k | ($1.9m) | $1.4m | ($945k) | — | |
| Gain (Loss) Related to Litigation Settlement | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss | $8k | — | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($264k) | $1.1m | ($474k) | ($314k) | $1.4m | $231k | $974k | $1.6m | ($3.3m) | $11.6m | — | |
| Interest Expense (non-operating) | $800k | $1.2m | $9.8m | $18.8m | $19.1m | $20.1m | $11.3m | $11.3m | $11.2m | $10.7m | $9.5m | |
| Interest Income (Expense), Nonoperating, Net | ($759k) | ($1.2m) | — | — | — | ($20.1m) | ($11.3m) | ($11.3m) | — | — | $11.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($57.6m) | ($58.4m) | ($101.9m) | ($146.4m) | ($188.8m) | ($179.7m) | ($278.2m) | ($376.1m) | ($320.5m) | ($49.3m) | ($67.1m) | |
| Current Income Tax Expense (Benefit) | $13.0m | $7.8m | $811k | ($21k) | ($19.4m) | $409k | $313k | $223k | $120k | $988k | $605k | |
| Income Tax Expense (Benefit) | ($9.7m) | $1.4m | $811k | ($21k) | ($19.4m) | $409k | $313k | $223k | $120k | $988k | $605k | |
| Net Income (Loss) Attributable to Parent | ($47.9m) |
($59.7m)
-24.69%
|
($102.7m)
-71.90%
|
($146.4m)
-42.61%
|
($169.4m)
-15.71%
|
($180.1m)
-6.29%
|
($278.5m)
-54.63%
|
($111.4m)
+60.00%
|
($321.5m)
-188.64%
|
($25.5m)
+92.06%
|
($43.5m)
-70.14%
|
|
| Earnings Per Share, Basic | ($1.29) | ($1.54) | ($2.54) | ($3.46) | ($3.56) | ($3.01) | ($4.37) | ($1.50) | ($4.08) | ($0.29) | ($0.46) | |
| Earnings Per Share, Diluted | ($1.29) | ($1.54) | ($2.54) | ($3.46) | ($3.56) | ($3.01) | ($4.37) | ($1.50) | ($4.08) | ($0.29) | ($0.46) | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | — | — | ($4) | ($5) | ($5) | ($4) | ($1) | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | — | — | ($4) | ($5) | ($5) | ($4) | ($1) | — | |
| Weighted Average Number of Shares Outstanding, Basic | 37.0m | 38.8m | 40.4m | 42.3m | 47.5m | 59.8m | 63.8m | 74.3m | 78.9m | 89.2m | 91.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | 38.3m | 38.8m | 40.4m | 42.3m | 47.5m | 59.8m | 63.8m | 74.3m | 78.9m | 89.2m | 91.2m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | $312.7m | $374.5m | $389.3m | $478.6m | $533.4m | $557.0m | $553.6m | — | |
| Goodwill, Impairment Loss | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $57.6m | $58.4m | $101.9m | $146.4m | $188.8m | $179.7m | $278.2m | ($376.3m) | ($320.6m) | ($50.3m) | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | $37.2m | $53.0m | $264.9m | ($915k) | $24.7m | — |